Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals are trading higher Monday after the company reported positive data from an ongoing trial.

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The opportunity to explore a multi-genre universe in innovative ways is extremely exciting. Matt ...

Few would place Recursion Pharmaceuticals (NASDAQ: RXRX), a little-known biotech company, in the same league as these tech giants when it comes to AI stocks. But could the small drugmaker actually ...

Recursion Pharmaceuticals ( RXRX +1.91%) was in the headlines on Monday, and for the right reason. One of the biotech company ...

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 6.5% in that time frame, outperforming the S&P 500. But investors have to be ...

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.